LeMaitre Vascular, Inc. — Cyborg Score 8/10

Strong
Medical Devices - Vascular Surgery

Strategic Profile

LeMaitre's 14% annualized revenue growth over the last five years was solid and beat the average healthcare company, showing its offerings resonate with customers. The company is positioned as a key player in the niche market of vascular surgery devices. Recent momentum is fueled by international expansion, particularly in EMEA and APAC regions, and strong product performance in high-margin categories.

Cyborg Score Rationale

LeMaitre reported a 16% increase in Q4 2025 sales and a 47% rise in operating income. The company forecasts 2026 revenue of $280 million with a 12% organic sales growth. Strong financial health, consistent execution, analyst upgrades, and shareholder returns underscore operational excellence.

Top Insights

  • The company achieved a gross margin of 71.7%, with notable growth in product categories like grafts, valvulotomes, and shunts, with geographic improvements including EMEA up 29%, APAC 20%, and the Americas 10%.
  • A $100 million share repurchase program and a 25% dividend increase have been announced.
  • The company exhibits strong financial health with a current ratio of 13.58 and a quick ratio of 11.81, and a debt-to-equity ratio of 0.49.
  • Analysts are updating views after Q4 results, tying moves to double digit organic sales growth, margin expansion and stronger cash flow.

Named Competitors

  • Vascular Access/Dialysis Grafts — Diversified medical device leader with competing vascular graft offerings
  • Specialty Vascular Devices — Cardiac and vascular surgery device manufacturer
  • Biologic Grafts — Established manufacturer of vascular grafts and patches

Recent Developments

  • (February 2026) Q4 2025 beat on revenue and EPS with 16% sales growth and 47% operating income growth; raised FY2026 guidance
  • (February 2026) Increased quarterly dividend 25% to $0.25/share and announced $100M share repurchase program
  • (February 2026) Analyst upgrades from Roth MKM ($117 target) and Citizens JMP ($118 target); Wells Fargo raised to $94

Open the full interactive LeMaitre Vascular, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →